Lianna J. Marks

508 total citations
21 papers, 137 citations indexed

About

Lianna J. Marks is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Lianna J. Marks has authored 21 papers receiving a total of 137 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 11 papers in Oncology and 6 papers in Neurology. Recurrent topics in Lianna J. Marks's work include Lymphoma Diagnosis and Treatment (11 papers), CNS Lymphoma Diagnosis and Treatment (6 papers) and Viral-associated cancers and disorders (5 papers). Lianna J. Marks is often cited by papers focused on Lymphoma Diagnosis and Treatment (11 papers), CNS Lymphoma Diagnosis and Treatment (6 papers) and Viral-associated cancers and disorders (5 papers). Lianna J. Marks collaborates with scholars based in United States, Canada and United Kingdom. Lianna J. Marks's co-authors include Philip LaRussa, Richard Idro, Phillip Kasirye, Deogratias Munube, Ezekiel Mupere, Zhezhen Jin, Nancy Green, Марина Москаленко, Maria Elena Pero and Vikas R. Dharnidharka and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biochemical Journal.

In The Last Decade

Lianna J. Marks

18 papers receiving 134 citations

Peers

Countries citing papers authored by Lianna J. Marks

Since Specialization

Citations

This map shows the geographic impact of Lianna J. Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lianna J. Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lianna J. Marks more than expected).

Fields of papers citing papers by Lianna J. Marks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lianna J. Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lianna J. Marks. The network helps show where Lianna J. Marks may publish in the future.

Co-authorship network of co-authors of Lianna J. Marks

This figure shows the co-authorship network connecting the top 25 collaborators of Lianna J. Marks. A scholar is included among the top collaborators of Lianna J. Marks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lianna J. Marks. Lianna J. Marks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Advances and updates in pediatric anaplastic large cell lymphoma 2025 ·Blood Advances ·Lianna J. Marks, Eric Lowe, Kala Y. Kamdar	0
2	PET Response and Outcome in Low‐Risk Nodular Lymphocyte‐Predominant Hodgkin Lymphoma: Children's Oncology Group Study AHOD03P1 2025 ·Pediatric Blood & Cancer ·Lianna J. Marks, Yue Wu, Kathleen M. McCarten, Lindsay A. Renfro, Qinglin Pei, Kara M. Kelly, Cindy L. Schwartz, Sharon M. Castellino, Burton Appel	1
3	Post-Transplant Lymphoproliferative Disorders 2024 ·Seminars in Nephrology ·Vikas R. Dharnidharka, Marianna B. Ruzinova, Lianna J. Marks	8
4	Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma 2023 ·Best Practice & Research Clinical Haematology ·Yaya Chu, (unknown), Caroline Diorio, Lianna J. Marks, Eric Lowe, David T. Teachey, Mitchell S. Cairo	3
5	Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma 2023 ·Blood Advances ·Christopher J. Forlenza, (unknown), Audrey Mauguen, Ilia N. Buhtoiarov, Branko Cuglievan, Hema Dave, Rebecca Deyell, Jamie E. Flerlage, (unknown), (unknown), Kasey J. Leger, Lianna J. Marks, Robin E. Norris, (unknown), (unknown), (unknown), Paul Harker‐Murray, Lisa Giulino‐Roth	3
6	Validation of Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event-Free Survival in Intermediate and High-Risk Hodgkin Lymphoma 2023 ·Blood ·Lianna J. Marks, Yiwang Zhou, Ying Zheng, Angela M. Feraco, Alison M. Friedmann, Howard J. Weinstein, Michael P. Link, Jamie E. Flerlage	1
7	Development of clinical pathways to improve multidisciplinary care of high-risk pediatric oncology patients 2022 ·Frontiers in Oncology ·Agnes Reschke, Rebecca M. Richards, Stephanie M. Smith, Adrienne H. Long, Lianna J. Marks, Liora M. Schultz, (unknown), Catherine Aftandilian, Kara L. Davis, Tanja A. Grüber, Kathleen M. Sakamoto	2
8	Pediatric EBV-negative monomorphic post–solid organ transplant lymphoproliferative disorders [EBV(-)M-PTLD]: Characteristics, treatment, and outcome from 11 pediatric academic centers. 2022 ·Journal of Clinical Oncology ·Zeinab Afify, Mary Taj, (unknown), Tamara P. Miller, (unknown), Mansi Dalal, (unknown), (unknown), Matthew J. Ehrhardt, (unknown), Jeremy D. Rubinstein, (unknown), (unknown), Karen M. Chisholm, (unknown), (unknown), (unknown), Lianna J. Marks, Christine M. Smith, Clinton C. Mason	0
9	Improving Risk Stratification to Guide Treatment Decisions for Children, Adolescents, and Young Adults With Hodgkin Lymphoma 2021 ·Journal of the National Comprehensive Cancer Network ·Lianna J. Marks	2
10	Brentuximab Vedotin As Consolidation Therapy Following Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Center Retrospective Analysis 2021 ·Blood ·Christopher J. Forlenza, (unknown), Audrey Mauguen, Ilia N. Buhtoiarov, Branko Cuglievan, Hema Dave, Rebecca Deyell, (unknown), Anna R. Franklin, (unknown), Kasey J. Leger, Lianna J. Marks, Robin E. Norris, (unknown), (unknown), (unknown), Paul Harker‐Murray, Lisa Roth	3
11	Expert consensus statements for Waldeyer's ring involvement in pediatric Hodgkin lymphoma: The staging, evaluation, and response criteria harmonization (SEARCH) for childhood, adolescent, and young adult Hodgkin lymphoma (CAYAHL) group 2020 ·Pediatric Blood & Cancer ·(unknown), Pedro A. de Alarcón, Jamie E. Flerlage, Bradford S. Hoppe, Sue C. Kaste, Kara M. Kelly, Lars Kurch, Lianna J. Marks, Christine Mauz‐Koerholz, Kathleen M. McCarten, Monika L. Metzger, Dietrich Stoevesandt, Stephan D. Voss, Angela Punnett	4
12	Preclinical evaluation of XPO1 inhibition in Wilms tumors. 2020 ·Journal of Clinical Oncology ·Michael V. Ortiz, (unknown), Daoqi You, Prabhjot S. Mundi, Lianna J. Marks, (unknown), Daniel Diolaiti, Mahalaxmi Aburi, Andrea Califano, Filemon S. Dela Cruz, Andrew L. Kung	0
13	Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (<18 y) With Early Relapse Hodgkin Lymphoma 2019 ·Journal of Pediatric Hematology/Oncology ·Karen S. Fernández, Melissa Mavers, Lianna J. Marks, Rajni Agarwal	4
14	Stroke Prevalence in Children With Sickle Cell Disease in Sub-Saharan Africa: A Systematic Review and Meta-Analysis 2018 ·Global Pediatric Health ·Lianna J. Marks, Deogratias Munube, Phillip Kasirye, Ezekiel Mupere, Zhezhen Jin, Philip LaRussa, Richard Idro, Nancy Green	28
15	Outcomes in intermediate‐risk pediatric lymphocyte‐predominant Hodgkin lymphoma: A report from the Children's Oncology Group 2018 ·Pediatric Blood & Cancer ·Lianna J. Marks, Qinglin Pei, Rizvan Bush, Allen Buxton, Burton Appel, Kara M. Kelly, Cindy L. Schwartz, Debra L. Friedman	11
16	Preclinical effect of selinexor (KPT-330), a selective inhibitor of nuclear export, in pediatric rhabdoid tumors. 2018 ·Journal of Clinical Oncology ·Lianna J. Marks, Daniel Diolaiti, Prabhjot S. Mundi, (unknown), (unknown), Filemon S. Dela Cruz, Andrea Califano, Andrew L. Kung	3
17	Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience 2017 ·Frontiers in Pediatrics ·Lianna J. Marks, Jennifer A. Oberg, Danielle Pendrick, Anthony Sireci, Chana L. Glasser, (unknown), (unknown), Wendy K. Chung, (unknown), Andrew T. Turk, Susan J. Hsiao, Mahesh Mansukhani, Julia Glade Bender, Andrew L. Kung, Maria Luisa Sulis	21
18	Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse 2017 ·Journal of Pediatric Hematology/Oncology ·Chana L. Glasser, (unknown), Don Eslin, Lianna J. Marks, Shakeel Modak, Julia Glade Bender	7
19	A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma 2016 ·Genome Medicine ·Filemon S. Dela Cruz, Daniel Diolaiti, Andrew T. Turk, (unknown), Alberto Ambesi‐Impiombato, Stuart Andrews, Mahesh Mansukhani, Péter L. Nagy, Mariano J. Alvarez, Andrea Califano, F. Forouhar, (unknown), Chelsey M. Mitchell, Darrell J. Yamashiro, Lianna J. Marks, Julia Glade Bender, Andrew L. Kung	14
20	Molecular Profiling of High-Risk Pediatric Acute Myeloid Leukemia 2016 ·Blood ·Lianna J. Marks, Jennifer A. Oberg, Julia Glade Bender, Susan J. Hsiao, Danielle Pendrick, Anthony Sireci, Stuart Andrews, Mahesh Mansukhani, Andrew L. Kung, Maria Luisa Sulis	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact